The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation
GenNext and Kiko Tech will provide sales and marketing, customer service, technical support, training, and related logistical efforts for Flash Oxidation Protein Footprinting Systems.
Revolutionary ovarian cancer rapid test available Q4 2022
The company exports mobile surgery equipment to over 100 countries from Pune
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Subscribe To Our Newsletter & Stay Updated
